Join the 'Xarelto' group to help and get support from people like you.

Xarelto Blog

Most Treatments for Blood Clots Appear Safe, Effective

Posted 16 Sep 2014 by Drugs.com

TUESDAY, Sept. 16, 2014 – Almost all the various treatment options for blood clots that form in veins are equally safe and effective, new research shows. In exploring the safety and effectiveness of treatments for such blood clots as deep vein thrombosis or pulmonary embolism (blood clot in a lung), Canadian researchers analyzed outcomes associated with eight blood-thinning options, including unfractionated heparin, low-molecular-weight heparin (LMWH) and fondaparinux in combination with vitamin K antagonists. The investigators also examined LMWH with dabigatran (Pradaxa), edoxaban, rivaroxaban (Xarelto), apixaban (Eliquis), as well as LMWH alone. After examining nearly 50 randomized studies, the researchers found that unfractionated heparin combined with vitamin K antagonist was associated with a higher percentage of recurrent blood clots over the course of three months than the ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Pulmonary Embolism, Heparin, Deep Vein Thrombosis, Eliquis, Rivaroxaban, Thrombotic/Thromboembolic Disorder, Arixtra, Hep-Pak, Fondaparinux, Dabigatran, Heparin Sodium, Apixaban, Venous Thromboembolism, Pulmonary Thromboembolism, Arixtra 10 mg/dose, Arixtra 7.5 mg/dose, Hep-Pak CVC

Study: Aspirin Might Work Instead of Warfarin for Deep Vein Clots

Posted 26 Aug 2014 by Drugs.com

TUESDAY, Aug. 26, 2014 – Aspirin may offer an alternative for people who've had blood clots in the deep veins of the legs and can't tolerate long-term use of blood thinners, according to Australian researchers. The condition, called deep vein thrombosis (DVT), can be life-threatening if clots break loose, travel to the lungs and block a pulmonary artery. Patients are usually prescribed blood thinners such as warfarin to prevent clot formation, the researchers noted. "Most people who have had a blood clot in a leg vein or an embolism where the clot blocks the blood flow have anticoagulant drug treatment, such as warfarin, for at least six months, first to dissolve the clot and then to prevent it happening again," said lead researcher Dr. John Simes, a professor of medicine at the University of Sydney. However, long-term use of warfarin (Coumadin) can be inconvenient, requiring frequent ... Read more

Related support groups: Aspirin, Coumadin, Warfarin, Xarelto, Deep Vein Thrombosis (DVT), Pradaxa, Deep Vein Thrombosis, Ecotrin, Rivaroxaban, Bayer Aspirin, Bufferin, Jantoven, Dabigatran, Ascriptin, Low Dose ASA, Aspergum, Easprin, ZORprin, Buffered Aspirin, Ascriptin Enteric

Pros, Cons to Dissolving Lung Clots: Study

Posted 17 Jun 2014 by Drugs.com

TUESDAY, June 17, 2014 – Drugs used to break up blood clots in the lungs may lower the risk of death, but they also increase the risk of bleeding, a new study finds. Researchers analyzed data from 16 trials involving use of clot-busting drugs called thrombolytics to treat life-threatening clots in the lungs (pulmonary embolism). Despite the drugs' apparent life-saving benefits, the risk of major bleeding, particularly in the brain, remains a concern, experts say. "The study advances our understanding, but is not enough to provide a definitive recommendation for use in all patients," said Dr. Joshua Beckman, director of the cardiovascular fellowship program at Brigham and Women's Hospital in Boston, who was not involved in the study. The evidence suggests that clot-busting therapy has merit but needs more study to refine the method by which it is given and to whom, added Beckman. What's ... Read more

Related support groups: Xarelto, Pradaxa, Pulmonary Embolism, Heparin, Rivaroxaban, Arixtra, Hep-Pak, Dabigatran, Fondaparinux, Activase, Heparin Sodium, Streptokinase, Streptase, Alteplase, Urokinase, Cathflo Activase, Kabikinase, Arixtra 10 mg/dose, Arixtra 7.5 mg/dose, Abbokinase Open-Cath

Doctors' Groups Issue New Guidelines on Treating Common Irregular Heartbeat

Posted 28 Mar 2014 by Drugs.com

FRIDAY, March 28, 2014 – Reduced use of aspirin and the addition of three new blood thinners as treatment options are among the recommendations in updated guidelines to manage a heart rhythm disorder called atrial fibrillation, which is a major risk factor for stroke. According to the American Heart Association, atrial fibrillation involves rapid and disorganized electrical signals that cause the heart's two upper chambers – the atria – to contract rapidly and irregularly. Symptoms can include rapid and irregular heartbeat, heart palpitations, shortness of breath, dizziness, sweating, fatigue or chest pain. Atrial fibrillation is not a fatal condition, but it can increase a person's risk of stroke five-fold. That's because atrial fibrillation allows blood to pool in the atria and form clots, the AHA said. One study published in November at the AHA's annual meeting found that ... Read more

Related support groups: Aspirin, Coumadin, Warfarin, Atrial Fibrillation, Xarelto, Pradaxa, Prevention of Thromboembolism in Atrial Fibrillation, Ecotrin, Eliquis, Rivaroxaban, Bayer Aspirin, Bufferin, Jantoven, Dabigatran, Apixaban, Low Dose ASA, St Joseph Aspirin, Aspergum, Easprin, ZORprin

Blood Thinners Now Recommended for People With Irregular Heartbeat

Posted 24 Feb 2014 by Drugs.com

MONDAY, Feb. 24, 2014 – People with an irregular heartbeat should take blood thinners to reduce their risk of stroke, an updated American Academy of Neurology (AAN) guideline recommends. Taking these drugs is especially important for people with irregular heartbeat who have already had a stroke or mini-stroke, experts say. Irregular heartbeat (atrial fibrillation) is a major risk factor for stroke because it causes blood to remain in the heart's upper chambers, according to the AAN. The blood can then form clots that can escape the heart and travel to the brain and cause a stroke. About 5 percent of people with untreated atrial fibrillation are likely to suffer a stroke within the next year, the neurology group pointed out. Blood thinners (anticoagulants) are highly effective in preventing strokes, but may cause bleeding and should be used only under close medical supervision, ... Read more

Related support groups: Xarelto, Pradaxa, Prevention of Thromboembolism in Atrial Fibrillation, Eliquis, Rivaroxaban, Dabigatran, Apixaban

Xarelto's Approval Expanded

Posted 5 Nov 2012 by Drugs.com

MONDAY, Nov. 5 – Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism. DVT occurs when a blood clot forms in a vein deep in the body. If a clot breaks away and travels to an artery in the lungs, it becomes a potentially deadly condition called a pulmonary embolism. Xarelto was approved last year to treat clots stemming from knee or hip replacement and to lessen the risk of stroke in people with a form of abnormal heart rhythm called non-valvular atrial fibrillation. The drug's newest approvals were given based on clinical studies involving 9,478 people, the FDA said in a news release. As with other anti-clotting drugs, bleeding is the most common side effect. Xarelto is produced by Janssen Pharmaceuticals, based in Raritan, N.J. More information The FDA ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Deep Vein Thrombosis, Rivaroxaban

FDA Expands Use of Xarelto to Treat, Reduce Recurrence of Blood Clots

Posted 2 Nov 2012 by Drugs.com

November 2, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment. Blood clots occur when blood thickens and clumps together. DVT is a blood clot that forms in a vein deep in the body. Most deep vein blood clots occur in the lower leg or thigh. When a blood clot in a deep vein breaks off and travels to an artery in the lungs and blocks blood flow, it results in a potentially deadly condition called PE. Xarelto is already FDA-approved to reduce the risk of DVTs and PEs from occurring after knee or hip replacement surgery (July 2011), and to reduce the risk of stroke in people who have a type of abnormal heart rhythm called non-valvular atrial fibrillation (November 2011). The FDA reviewed ... Read more

Related support groups: Xarelto, Deep Vein Thrombosis (DVT), Pulmonary Embolism, Deep Vein Thrombosis - First Event, Deep Vein Thrombosis, Deep Vein Thrombosis - Recurrent Event, Rivaroxaban, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis Prophylaxis after Abdominal Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Orthopedic Surgery, Deep Vein Thrombosis Prophylaxis after General Surgery

Irregular Heartbeat May Pose Higher Stroke Risk for Women Than Men

Posted 31 Aug 2012 by Drugs.com

FRIDAY, Aug. 31 – Women older than 75 who have a heart rhythm disorder called atrial fibrillation are 20 percent more likely to have a stroke than men in the same age group with atrial fibrillation, according to a large new study. However, researchers said the findings suggest that being a woman should not be included as an independent risk factor for stroke or blood clots, either in guidelines for treatment or risk assessment of patients with atrial fibrillation, because the difference doesn't hold for women younger than 75. The study included more than 87,000 atrial fibrillation patients in Denmark. Of those patients, more than 51 percent were female. After one year of follow-up, female patients younger than 75 did not have an increased risk of stroke, but those over age 75 had a 20 percent increased risk, the investigators found. The study was presented Sunday at the European ... Read more

Related support groups: Coumadin, Warfarin, Atrial Fibrillation, Xarelto, Pradaxa, Lovenox, Heparin, Prevention of Thromboembolism in Atrial Fibrillation, Enoxaparin, Clexane, Rivaroxaban, Fragmin, Arixtra, Hep-Pak, Dalteparin, Jantoven, Dabigatran, Fondaparinux, Innohep, Normiflo

Quick-Reversal Method May Be at Hand for New Blood Thinner

Posted 20 Jun 2012 by Drugs.com

WEDNESDAY, June 20 – Newer blood-thinning drugs sometimes have one drawback: In cases where they trigger bleeding, their effects can be tough to reverse compared to the standard anticoagulant, warfarin. Now, a new study finds there are three different approaches to reverse the action of one new blood thinner, apixaban (Eliquis) – a drug that's currently under review by the U.S. Federal Drug Administration. Researchers in Spain noted that it remains unclear which method for reversing this new drug might be best. "If you have an accident or need emergency surgery, doctors have three ways to reverse [the older, standby blood-thinner] warfarin that work in a matter of minutes to hours. In contrast, there is little information on how best to reverse the effects of newer anticoagulants, which can take 10 to 18 hours," study author Dr. Gines Escolar, an associate professor of hematology at ... Read more

Related support groups: Coumadin, Warfarin, Xarelto, Rivaroxaban, Jantoven

FDA Panel Votes Against New Use for Blood Thinner Xarelto

Posted 24 May 2012 by Drugs.com

WEDNESDAY, May 23 – An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner, Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome. The panel of experts voted 6-to-4, with one member abstaining, against using the drug in these high-risk patients. Panel members said there wasn't enough data in company studies to definitively assess the medication's benefit at this time, the Associated Press reported. The decision came as something of a surprise, since FDA briefing documents filed Monday in advance of the panel meeting looked more favorably on the drug. A final decision from the FDA is expected June 29. The FDA is not required to follow the advice of its advisory panels, but it typically does. Xarelto (rivaroxaban) is one of a new class of blood thinners that has been developed to ... Read more

Related support groups: Xarelto, Acute Coronary Syndrome, Rivaroxaban

New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA

Posted 21 May 2012 by Drugs.com

MONDAY, May 21 – The new blood thinner Xarelto appears to lower the chances of potentially fatal blood clots in high-risk heart patients, a U.S. Food and Drug Administration review has found. The review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart). The FDA is not required to follow the advice of its expert panels, but the agency typically does. A final decision is expected by the end of June, according to the documents. Xarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose ... Read more

Related support groups: Atrial Fibrillation, Xarelto, Prevention of Thromboembolism in Atrial Fibrillation, Acute Coronary Syndrome, Rivaroxaban

Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat

Posted 25 Apr 2012 by Drugs.com

WEDNESDAY, April 25 – When patients with atrial fibrillation stop taking anti-clotting drugs, their stroke risk goes up quickly, new research finds. That risk increases about the same whether they are taking warfarin or a newer, more expensive drug, Xarelto (rivaroxaban). Atrial fibrillation is an abnormal heart rhythm in which the upper chambers of the heart quiver or flutter instead of contracting correctly, raising the risk of stroke fivefold. Patients are often put on anti-clotting drugs to ward off stroke. But some people need to temporarily stop taking anti-clotting drugs before surgery or other medical procedures to prevent excess bleeding, while other patients permanently stop taking anti-clotting drugs because of side effects, researchers said. Researchers analyzed data from a previous trial including more than 14,000 patients with atrial fibrillation. In that trial, ... Read more

Related support groups: Coumadin, Warfarin, Atrial Fibrillation, Xarelto, Pradaxa, Prevention of Thromboembolism in Atrial Fibrillation, Rivaroxaban, Jantoven, Dabigatran

New Anti-Clotting Drug May Cut Brain Bleeding Risk: Study

Posted 2 Feb 2012 by Drugs.com

THURSDAY, Feb. 2 – A new medication that helps prevent strokes in people with the abnormal heart rhythm disorder known as atrial fibrillation poses less risk of bleeding in the brain than a commonly used drug, research comparing rivaroxaban (Xarelto) and warfarin suggests. Anti-clotting medications, also called blood-thinners or anticoagulants, include warfarin (Coumadin) and aspirin, among others. In patients with atrial fibrillation, these drugs can reduce the risk of ischemic stroke, which occurs when a vessel becomes clogged by a blood clot. But the drugs can also cause excessive bleeding because they make it harder for blood to clot. In a new study, researchers led by Dr. Graeme Hankey, a neurologist at the Royal Perth Hospital and University of Western Australia, followed more than 14,000 people who took anti-clotting drugs for a median of two years. Of those patients, 136 had ... Read more

Related support groups: Xarelto, Prevention of Thromboembolism in Atrial Fibrillation, Rivaroxaban

Blood Thinner Xarelto Shows Promise for Heart Patients

Posted 13 Nov 2011 by Drugs.com

SUNDAY, Nov. 13 – When added to standard treatment, a new blood-thinning drug called Xarelto (rivaroxaban) may help people with "acute coronary syndrome" lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is an umbrella term that includes people with angina or prior history of heart attack. The finding "opens up a new area for treating this very common condition," said study co-author Dr. Eugene Braunwald, professor of medicine at Harvard Medical School and a cardiologist at Brigham and Women's Hospital in Boston. The study could help Xarelto expand the ranks of common blood thinners, which for decades were dominated by old standbys such as warfarin (Coumadin) or, more recently, Plavix (clopidogrel). Xarelto is currently approved by the U.S Food and Drug Administration to treat an abnormal heart rhythm called atrial fibrillation and ... Read more

Related support groups: Xarelto, Acute Coronary Syndrome

FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm

Posted 4 Nov 2011 by Drugs.com

SILVER SPRING, Md., Nov. 4, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). Atrial fibrillation occurs in more than 2 million Americans and is one of the most common types of abnormal heart rhythm. In atrial fibrillation, the beating of the heart's two upper heart chambers (atria) is irregular and poorly coordinated. This leads to blood pooling in these chambers, resulting in blood clots. Non-valvular atrial fibrillation refers to atrial fibrillation in patients who do not have significant problems in their heart valves. "Atrial fibrillation can lead to the formation of blood clots, which can travel to the brain, blocking blood flow and causing a disabling stroke," said Norman Stockbridge, M.D., ... Read more

Related support groups: Xarelto, Prevention of Thromboembolism in Atrial Fibrillation, Rivaroxaban

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Atrial Fibrillation, Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Pulmonary Embolism, Deep Vein Thrombosis - Prophylaxis, Pulmonary Embolism - Recurrent Event, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis - Recurrent Event, Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery

Xarelto Patient Information at Drugs.com